Do contemporary antiretrovirals increase the risk of end‐stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design-Reference-Cited by-同舟云学术

Do contemporary antiretrovirals increase the risk of end‐stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design

Published:2021-11-23 Issue:2 Volume:31 Page:214-224
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiology and Drug

Author:

Young Jim¹²^ORCID,Lo Re Vincent³,Kim H. Nina⁴,Sterling Timothy R.⁵,Althoff Keri N.⁶,Gebo Kelly A.⁷,Gill M. John⁸,Horberg Michael A.⁹,Mayor Angel M.¹⁰,Moore Richard D.⁷,Silverberg Michael J.¹¹,Klein Marina B.¹²¹²,

Affiliation:

1. Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, Glen Site McGill University Health Centre Montreal Quebec Canada

2. Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine McGill University Montreal Quebec Canada

3. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

4. Department of Medicine University of Washington Seattle Washington USA

5. Division of Infectious Diseases Vanderbilt University Medical Center Nashville Tennessee USA

6. Department of Epidemiology Johns Hopkins University Bloomberg School of Public Health Baltimore Maryland USA

7. Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA

8. Department of Medicine University of Calgary Calgary Alberta Canada

9. Kaiser Permanente Mid‐Atlantic States Mid‐Atlantic Permanente Research Institute Rockville Maryland USA

10. Retrovirus Research Center, Internal Medicine Department, School of Medicine Universidad Central del Caribe Bayamón Puerto Rico USA

11. Division of Research Kaiser Permanente Northern California Oakland California USA

12. CIHR Canadian HIV Trials Network Vancouver British Columbia Canada

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5379

Reference49 articles.

1. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

2. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons

3. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection

4. The value of screening HIV-infected individuals for didanosine-related liver disease?

5. A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contagious order as a risk factor for liver fibrosis progression in co-infection with human immunodeficiency virus, hepatitis B and C viruses;Journal Infectology;2024-01-11

2. Semiparametric Bayesian inference for optimal dynamic treatment regimes via dynamic marginal structural models;Biostatistics;2022-04-06

3. Advances in Liver Transplantation for Persons with Human Immunodeficiency Infection;Current Infectious Disease Reports;2022-03